JP2007504260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504260A5 JP2007504260A5 JP2006525712A JP2006525712A JP2007504260A5 JP 2007504260 A5 JP2007504260 A5 JP 2007504260A5 JP 2006525712 A JP2006525712 A JP 2006525712A JP 2006525712 A JP2006525712 A JP 2006525712A JP 2007504260 A5 JP2007504260 A5 JP 2007504260A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- interferon
- treatment
- liver diseases
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015181 infectious disease Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320638.0A GB0320638D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| GB0320638.0 | 2003-09-03 | ||
| PCT/EP2004/009804 WO2005021028A1 (en) | 2003-09-03 | 2004-09-02 | Use of modified cyclosporins for the treatment of hcv disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504260A JP2007504260A (ja) | 2007-03-01 |
| JP2007504260A5 true JP2007504260A5 (OSRAM) | 2007-10-11 |
| JP4688806B2 JP4688806B2 (ja) | 2011-05-25 |
Family
ID=28686843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525712A Expired - Fee Related JP4688806B2 (ja) | 2003-09-03 | 2004-09-02 | Ｈｃｖ障害の処置のための修飾シクロスポリンの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7968518B2 (OSRAM) |
| EP (2) | EP1797892B1 (OSRAM) |
| JP (1) | JP4688806B2 (OSRAM) |
| KR (1) | KR101116968B1 (OSRAM) |
| CN (1) | CN1842343A (OSRAM) |
| AU (2) | AU2004268382A1 (OSRAM) |
| BR (1) | BRPI0414062B8 (OSRAM) |
| CA (1) | CA2537137C (OSRAM) |
| CY (1) | CY1110506T1 (OSRAM) |
| DE (1) | DE602004022061D1 (OSRAM) |
| DK (1) | DK1663287T3 (OSRAM) |
| ES (1) | ES2328361T3 (OSRAM) |
| GB (1) | GB0320638D0 (OSRAM) |
| HR (1) | HRP20090535T1 (OSRAM) |
| IL (1) | IL173909A (OSRAM) |
| IS (1) | IS2917B (OSRAM) |
| MA (1) | MA28032A1 (OSRAM) |
| MX (1) | MXPA06002394A (OSRAM) |
| NO (1) | NO20061479L (OSRAM) |
| NZ (1) | NZ545495A (OSRAM) |
| PL (1) | PL1663287T3 (OSRAM) |
| PT (1) | PT1663287E (OSRAM) |
| RU (1) | RU2389501C2 (OSRAM) |
| SG (1) | SG149063A1 (OSRAM) |
| SI (1) | SI1663287T1 (OSRAM) |
| TN (1) | TNSN06071A1 (OSRAM) |
| TW (1) | TWI342782B (OSRAM) |
| WO (1) | WO2005021028A1 (OSRAM) |
| ZA (1) | ZA200601550B (OSRAM) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| CA2518265A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| GB0500020D0 (en) * | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| ATE497775T1 (de) * | 2004-07-14 | 2011-02-15 | Novartis Pharma Gmbh | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006039163A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| HRP20110169T1 (hr) | 2004-10-01 | 2011-04-30 | Debiopharm S.A. | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| ES2314731T3 (es) | 2004-11-22 | 2009-03-16 | Astellas Pharma Inc. | Analogo de ciclosporina. |
| KR20070087624A (ko) * | 2004-12-23 | 2007-08-28 | 노파르티스 아게 | Ｈｃｖ 치료용 조성물 |
| CN101084005A (zh) * | 2004-12-23 | 2007-12-05 | 诺瓦提斯公司 | 用于黄病毒科治疗的化合物 |
| CN101242842A (zh) * | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
| DE602006020152D1 (de) * | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| CN101316606B (zh) * | 2005-09-30 | 2015-05-27 | 西尼克斯公司 | 治疗和预防丙型肝炎感染的方法和药物组合物 |
| KR20080059270A (ko) * | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| PT1957518E (pt) * | 2005-10-26 | 2016-02-26 | Astellas Pharma Inc | Novos compostos peptídicos cíclicos |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| CN101511357B (zh) | 2006-05-19 | 2011-11-02 | 西尼克斯公司 | 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用 |
| EP2027761A1 (fr) * | 2006-06-02 | 2009-02-25 | Claude Annie Perrichon | Gestion des electrons actifs |
| BRPI0719189A2 (pt) * | 2006-10-12 | 2018-08-14 | Univ Kyushu Nat Univ Corp | uso de ciclosporinas modificadas |
| WO2008069917A2 (en) * | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| EP2124992A2 (en) | 2007-01-04 | 2009-12-02 | Debiopharm S.A. | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| KR20100017547A (ko) * | 2007-05-02 | 2010-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| WO2009028418A1 (ja) | 2007-08-24 | 2009-03-05 | Sapporo Medical University | シクロスポリンａ結合タンパク質 |
| US9090671B2 (en) | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| US20130190223A1 (en) * | 2008-07-30 | 2013-07-25 | Isotechnika Pharma Inc. | Nonimmunosuppressive cyclosporine analogue molecules |
| KR20110073473A (ko) * | 2008-09-24 | 2011-06-29 | 아스텔라스세이야쿠 가부시키가이샤 | 펩티드 화합물 및 그의 제조 방법 |
| CN102202679B (zh) * | 2008-11-06 | 2014-05-07 | 帝柏奥研究制药有限公司 | 环十一缩酚酸肽化合物及其作为药物的用途 |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| KR20110111321A (ko) | 2009-01-30 | 2011-10-10 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체 |
| US8481483B2 (en) | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8349312B2 (en) | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
| US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8685917B2 (en) | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| JP2013513595A (ja) | 2009-12-09 | 2013-04-22 | サイネクシス，インコーポレーテッド | 新規環状ペプチド |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| JP2013542206A (ja) | 2010-10-05 | 2013-11-21 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症の新規治療 |
| WO2012072655A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | New treatments of hepatitis c virus infection |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| KR102011339B1 (ko) | 2010-12-15 | 2019-08-16 | 콘트라빌 파마슈티컬스, 인코퍼레이티드 | 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자 |
| RU2013148539A (ru) | 2011-03-31 | 2015-05-10 | Новартис Аг | Алиспоривир для лечения инфекции вируса гепатита с |
| AU2012237295A1 (en) | 2011-04-01 | 2013-09-19 | Novartis Ag | Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases |
| RU2013150344A (ru) | 2011-04-13 | 2015-05-20 | Новартис Аг | Лечение инфекции вируса гепатита алисповиром |
| BR112014007247A2 (pt) | 2011-09-27 | 2017-03-28 | Novartis Ag | alisporivir para o tratamento de infecção por vírus da hepatite c |
| WO2013169616A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmacokinetic modulation with alisporivir |
| EP3263587A1 (en) | 2012-06-01 | 2018-01-03 | Allergan, Inc. | Cyclosporin a analogs |
| WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
| WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| RU2016110247A (ru) | 2013-08-26 | 2017-10-02 | Энанта Фармасьютикалс, Инк. | Аналоги циклоспорина для предупреждения или лечения гепатита с |
| WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
| WO2016073480A1 (en) | 2014-11-03 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Novel cyclosporin analogues for preventing or treating hepatitis c infection |
| TW201639873A (zh) | 2015-01-08 | 2016-11-16 | 歐樂根公司 | Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物 |
| WO2022043678A1 (en) * | 2020-08-24 | 2022-03-03 | Nanomerics Limited | Viral inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| DK0484281T4 (da) * | 1990-11-02 | 2001-02-05 | Novartis Ag | Cyclosporiner |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
| AU691225B2 (en) | 1993-11-10 | 1998-05-14 | Schering Corporation | Improved interferon polymer conjugates |
| ATE211726T1 (de) | 1994-08-22 | 2002-01-15 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DK1319651T3 (da) | 1997-04-04 | 2005-08-01 | Mitsubishi Pharma Corp | 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| SK152003A3 (en) | 2000-07-13 | 2004-07-07 | Sankyo Co | Amino alcohol derivatives |
| JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
| JP4232866B2 (ja) | 2000-10-19 | 2009-03-04 | 有限会社 ケアティス | 細胞障害抑制剤 |
| JP2002125683A (ja) * | 2000-10-27 | 2002-05-08 | Tokyoto Igaku Kenkyu Kiko | インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ |
| PL367348A1 (en) | 2001-03-26 | 2005-02-21 | Novartis Ag | 2-amino-propanol derivatives |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| CA2460640C (en) | 2001-09-27 | 2011-03-29 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same |
| JP4217620B2 (ja) | 2001-09-27 | 2009-02-04 | 杏林製薬株式会社 | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
| US20030213603A1 (en) | 2002-05-14 | 2003-11-20 | Fisher David B. | Dual use extension apparatus for a tool |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| GB0313444D0 (en) | 2003-06-11 | 2003-07-16 | Midland Medical Technologies L | Modular dysplasia cup |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| HRP20110169T1 (hr) | 2004-10-01 | 2011-04-30 | Debiopharm S.A. | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
| KR20070087624A (ko) | 2004-12-23 | 2007-08-28 | 노파르티스 아게 | Ｈｃｖ 치료용 조성물 |
-
2003
- 2003-09-03 GB GBGB0320638.0A patent/GB0320638D0/en not_active Ceased
-
2004
- 2004-09-02 PT PT04764762T patent/PT1663287E/pt unknown
- 2004-09-02 ES ES04764762T patent/ES2328361T3/es not_active Expired - Lifetime
- 2004-09-02 HR HR20090535T patent/HRP20090535T1/hr unknown
- 2004-09-02 EP EP06125649.1A patent/EP1797892B1/en not_active Expired - Lifetime
- 2004-09-02 RU RU2006110533/15A patent/RU2389501C2/ru not_active IP Right Cessation
- 2004-09-02 WO PCT/EP2004/009804 patent/WO2005021028A1/en not_active Ceased
- 2004-09-02 BR BRPI0414062A patent/BRPI0414062B8/pt not_active IP Right Cessation
- 2004-09-02 CA CA2537137A patent/CA2537137C/en not_active Expired - Fee Related
- 2004-09-02 NZ NZ545495A patent/NZ545495A/en not_active IP Right Cessation
- 2004-09-02 SI SI200431200T patent/SI1663287T1/sl unknown
- 2004-09-02 US US10/570,097 patent/US7968518B2/en active Active
- 2004-09-02 DK DK04764762T patent/DK1663287T3/da active
- 2004-09-02 CN CNA2004800246044A patent/CN1842343A/zh active Pending
- 2004-09-02 TW TW093126578A patent/TWI342782B/zh not_active IP Right Cessation
- 2004-09-02 KR KR1020067004342A patent/KR101116968B1/ko not_active Expired - Fee Related
- 2004-09-02 PL PL04764762T patent/PL1663287T3/pl unknown
- 2004-09-02 AU AU2004268382A patent/AU2004268382A1/en not_active Abandoned
- 2004-09-02 JP JP2006525712A patent/JP4688806B2/ja not_active Expired - Fee Related
- 2004-09-02 SG SG200809555-6A patent/SG149063A1/en unknown
- 2004-09-02 MX MXPA06002394A patent/MXPA06002394A/es active IP Right Grant
- 2004-09-02 EP EP04764762A patent/EP1663287B1/en not_active Expired - Lifetime
- 2004-09-02 DE DE602004022061T patent/DE602004022061D1/de not_active Expired - Lifetime
-
2006
- 2006-02-22 ZA ZA200601550A patent/ZA200601550B/en unknown
- 2006-02-23 IL IL173909A patent/IL173909A/en active IP Right Grant
- 2006-03-02 TN TNP2006000071A patent/TNSN06071A1/en unknown
- 2006-03-10 MA MA28865A patent/MA28032A1/fr unknown
- 2006-03-24 IS IS8371A patent/IS2917B/is unknown
- 2006-03-31 NO NO20061479A patent/NO20061479L/no not_active Application Discontinuation
-
2008
- 2008-07-09 AU AU2008203031A patent/AU2008203031B2/en not_active Ceased
-
2009
- 2009-09-16 CY CY20091100955T patent/CY1110506T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504260A5 (OSRAM) | ||
| JP2013529627A5 (OSRAM) | ||
| ATE473750T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| JP2018512453A5 (OSRAM) | ||
| EA200700718A1 (ru) | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения | |
| Dusheiko | Treatment and prevention of chronic viral hepatitis | |
| Chen et al. | Hepatitis C virus infection in Taiwan | |
| Abbas | Hepatitis D in pakistan | |
| Tao et al. | Seroepidemiology of HCV and HBV infection in northern China | |
| Müller | Pathogenicity of GBV‐C/HGV infection | |
| Pol et al. | Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialyis patients | |
| Liaw | Viral hepatitis in Taiwan: status in the 1990s | |
| Abraham | Treatment for hepatitis C virus infection in India: promising times | |
| Sharifi et al. | Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in Iran–preliminary report | |
| Aderka et al. | Does tumor necrosis factor play a role in the pathogenesis of fulminant hepatitis? | |
| Alavian | Hepatitis D is a forgotten problem in hemodialysis patients in the world | |
| Ibarra | Module XllTreatment of HBV–HCV coinfection | |
| Alavian | Optimal therapy for hepatitis C | |
| Mahmood | Studying the possibility of confection of hepatitis C and hepatitis G viruses in Iraqi patients | |
| Fenoglio et al. | Cryoglobulinemia and Emerging Related | |
| Russello et al. | Recombinant interferon alpha therapy in elderly patients with chronic hepatitis C without cirrhosis | |
| Maryam Maigari et al. | CAUSES AND CURRENT TRENDS IN THE DIAGNOSIS AND MANAGEMENT OF HEPATITIS C VIRUS INFECTION: A REVIEW | |
| Elefsiniotis et al. | Immunogenicity of recombinant hepatitis B vaccine in treatment-na ve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment | |
| Kamoliddin | CLINICAL FEATURES OF CHRONIC VIRAL HEPATITIS C, DUE TO CONSOLIDATED DISEASES |